Herpes simplex virus type 1 (HSV-1) is a prevalent microbial pathogen infecting 60% to 90% of the adult world population. The co-evolution of the virus with humans is due, in part, to adaptations that the virus has evolved to aid it in escaping immune surveillance, including the establishment of a latent infection in its human host. A latent infection allows the virus to remain in the host without inducing tissue pathology or eliciting an immune response. During the acute infection or reactivation of latent virus, the immune response is significant, which can ultimately result in corneal blindness or fatal sporadic encephalitis. In fact, HSV-1 is one of the leading causes of infectious corneal blindness in the world as a result of chronic episodes of viral reactivation leading to stromal keratitis and scarring. Significant inroads have been made in identifying key immune mediators that control ocular HSV-1 infection and potentially viral reactivation. Likewise, viral mechanisms associated with immune evasion have also been identified and will be discussed. Lastly, novel therapeutic strategies that are currently under development show promise and will be included in this review. Most investigators have taken full advantage of the murine host as a viable working in vivo model of HSV-1 due to the sensitivity and susceptibility to viral infection, ease of manipulation, and a multitude of developed probes to study changes at the cellular and molecular levels. Therefore, comments in this review will primarily be restricted to those observations pertaining to the mouse model and the assumption (however great) that similar events occur in the human condition.
RussellAS. Cell-mediated immunity to herpes simplex virus in man. J Infect Dis129:142–146, 1974.
2.
LopezC, O'ReillyRJ. Cell-mediated immune responses in recurrent herpesvirus infections. I. Lymphocyte proliferation assay. J Immunol118:895–902, 1977.
3.
RasmussenL, MeriganTC. Role of T lymphocytes in cellular immune responses during herpes simplex virus infection in humans. Proc Natl Acad Sci U S A75:3957–3961, 1978.
4.
NesburnAB. Immunological aspects of ocular herpes simplex disease. In: Immunology of the Eye: III. London: IRL Press Limited, pp21–42, 1978.
5.
ChandlerJW. Herpes keratitis and the immune system. Ophthalmic Forum2:189–194, 1984.
PeposeJS. Herpes simplex keratitis: Role of viral infection versus immune response. Surv Ophthalmol35:345–352, 1991.
8.
StrausSE, RooneyJF, SeverJL, SeidlinM, Nusinoff-LehrmanS, CremerK.Herpes simplex virus infection: Biology, treatment, and prevention. Ann Intern Med103:404–419, 1985.
9.
SimmonsA, TscharkeD, SpeckP.The role of immune mechanisms in control of herpes simplex virus infection of the peripheral nervous system. In: Current Topics in Microbiology and Immunology. Berlin: Springer-Verlag, Vol. 179:pp34–56, 1992.
10.
PereiraFA. Herpes simplex: Evolving concepts. J Am Acad Dermatol35:503–520, 1996.
MillerCS, DanaherRJ, JacobRJ. Molecular aspects of herpes simplex virus I latency, reactivation, and recurrence. Crit Rev Oral Biol Med9:541–562, 1998.
13.
DaheshiaM, FeldmanLT, RouseBT. Herpes simplex virus latency and the immune response. Curr Opin Microbiol1:430–435, 1998.
14.
FarrisRL. Abnormalities of the tears and treatment of dry eyes. In: KaufmanHE, BarronBA, and McDonaldMB, Eds. The Cornea. Boston: Butterworth-Heinemann, pp 109–130, 1998.
15.
KaufmanHE, MeyerRF, LaibsonPR, WaltmanSR, NesburnAB, ShusterJJ. Human leukocyte interferon for the prevention of recurrences of herpetic keratitis. J Infect Dis113(Suppl): A165–A169, 1976.
16.
Neumann-HaefelinD, SundmacherR, FreyH, MerkW.Recombinant HulFN-gamma prevents herpes simplex keratitis in African green monkeys: Demonstration of synergism with recombinant HulFN-alpha 2. Med Microbiol Immunol174:81–86, 1985.
17.
HendricksRL, WeberPC, TaylorJL, KoumbisA, TumpeyTM, GloriosoJC. Endogenously produced interferon-α protects mice from herpes simplex virus type 1 corneal disease. J Gen Virol72:1601–1610, 1991.
18.
ChenS-H, OakesJE, LauschRN. Synergistic anti-herpes effect of TNF-α and IFN-γ in human corneal epithelial cells compared with that in corneal fibroblasts. Antiviral Res25:201–213, 1994.
19.
BabuJS, KanagatS, RouseBT. T cell cytokine mRNA expression during the course of the immunopathologic ocular disease herpetic stromal keratitis. J Immunol154:4822–4829, 1995.
KlyceSD, BeuermanRW. Structure and function of the cornea. In: Kaufman HE, BarronBA, and McDonaldMB, Eds. The Cornea. Boston: Butterworth-Heinemann, pp3–50, 1998.
22.
SchangLM, PhillipsJ, SchafferPA. Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription. J Virol72:5626–5637, 1998.
23.
AdvaniSJ, BrandimartiR, WeichselbaumRR, RoizmanB.The disappearance of cyclins A and B and the increase in activity of the G2/M-phase cellular kinase cdc2 in herpes simplex virus 1-infected cells require expression of the α22/US1.5 and UL13 viral genes. J Virol74:8–15, 2000.
24.
SchangLM, RosenbergA, SchafferPA. Roscovitine, a specific inhibitor of cellular cyclin-dependent kinases, inhibits herpes simplex virus DNA synthesis in the presence of viral early proteins. J Virol74:2107–2120, 2000.
Meyers-ElliottRH, ChitjianPA. Immunopathogenesis of corneal inflammation in herpes simplex virus stromal keratitis; Role of the polymorphonuclear leukocyte. Invest Ophthalmol Vis Sci20:784–798, 1981.
27.
TulloAB, ShimeldC, BlythWA, HillTJ, EastyDL. Ocular infection with herpes simplex virus in nonimmune and immune mice. Arch Ophthalmol101:961–964, 1983.
28.
HendricksRL, TumpeyTM. Contribution of virus and immune factors to herpes simplex virus type I-induced corneal pathology. Invest Ophthalmol Vis Sci31:1929–1939, 1990.
29.
NiemialtowskiMG, RouseBT. Phenotypic and functional studies on ocular T cells during herpetic infections of the eye. J Immunol148:1864–1870, 1992.
30.
BrandiCR, SalkowskiCA. Activation of NK cells in mice following corneal infection with herpes simplex virus type-1. Invest Ophthalmol Vis Sci33:113–120, 1992.
31.
TumpeyTM, ChenS-H, OakesJE, LauschRN. Neutrophil-mediated suppression of virus replication after herpes simplex virus type 1 infection of the murine cornea. J Virol70:898–904, 1996.
32.
YanX-T, TumpeyTM, KunkelSL, OakesJE, LauschRN. Role of MIP-2 in neutrophil migration and tissue injury in the herpes simplex virus-1-infected cornea. Invest Ophthalmol Vis Sci39:1854–1862, 1998.
33.
GhiasiH, CaiS, PerngG-C, NesburnAB, WechslerSL. The role of natural killer cells in protection of mice against death and corneal scarring following ocular HSV-1 infection. Antiviral Res45:33–45, 2000.
34.
GangappaS, BabuJS, ThomasJ, DaheshiaM, RouseBT. Virus-induced immunoinflammatory lesions in the absence of viral antigen recognition. J Immunol161:4289–4300, 1998.
35.
ThomasJ, KanangatS, RouseBT. Herpes simplex virus replication-induced expression of chemokines and proinflammatory cytokines in the eye: Implications in herpetic stromal keratitis. J Interferon Cytokine Res18:681–690, 1998.
36.
ShimeldC, WhitelandJL, NichollsSM, EastyDL, HillTJ. Immune cell infiltration in corneas of mice with recurrent herpes simplex virus disease. J Gen Virol77:977–985, 1996.
37.
Lawkowicz-MossSJ, ShimeldC, LipworthK, HillTJ, BlythWA, EastyDL. Quantitative studies on Langerhans cells in mouse corneal epithelium following infection with herpes simplex virus. Exp Eye Res45:127–140, 1987.
38.
PeposeJ.The relationship of corneal Langerhans cells to herpes simplex antigens during dendritic keratitis. Curr Eye Res8:851–858, 1989.
39.
HendricksRL, JanowiczM, TumpeyTM. Critical role of corneal Langerhans cells in the CD4- but not CD8-mediated immunopathology in herpes simplex virus-1-infected mouse corneas. J Immunol148:2522–2529, 1992.
40.
JagerMJ, BradleyD, AthertonS, StreileinJW. Presence of Langerhans cells in the central cornea linked to the development of ocular herpes in mice. Exp Eye Res54:835–841, 1992.
41.
MillerJK, LaycockKA, NashMM, PeposeJS. Corneal Langerhans cell dynamics after herpes simplex virus reactivation. Invest Ophthalmol Vis Sci34:2282–2290, 1993.
42.
AllansmithMR. The Eye and Immunology. St. Louis: CV Mosby Company, 1982.
43.
VerjansGMGM, RemeijerL, van BinnendijkRS, CornelissenJGC, Volker-DiebenHJ, BaarsmaSG, OsterhausADME. Identification and characterization of herpes simple virus-specific CD4+ T cells in corneas of herpetic stromal keratitis patients. J Infect Dis177:484–488, 1998.
44.
KoelleDM, RymondSN, ChenH, KwokWW, McClurkanC, GyaltsongT, PetersdorfEW, RotkisW, TalleyAR, HarrisonDA. Tegument-specific, virus-reactive CD4 T cells localize to the cornea in herpes simplex virus interstitial keratitis in humans. J Virol74:10930–10938, 2000.
45.
CentifantoYM, LittleJM, KaufmanHE. The relationship between virus chemotherapy, secretory antibody formation and recurrent herpetic disease. Ann NY Acad Sci173:649–656, 1970.
46.
ShaniL, SzantonE, DavidR, YuassurY, SarovI.Studies on HSV-specific IgA antibodies in lacrimal fluid from patients with herpes keratitis by solid phase radioimmunoassay. Curr Eye Res4:103–111, 1985.
47.
FoxPD, KhawPT, McBrideBW, McGillJI, WardKA. Tear and serum antibody levels in ocular herpetic infection: Diagnostic precision of secretory IgA. Br J Ophthalmol70:584–588, 1986.
48.
MetcalfJF, KaufmanHE. Herpetic stromal keratitis: Evidence for cell-mediated immunopathogenesis. Am J Ophthalmol82:827–834, 1976.
TulloAB, ShimeldC, BlythWA, HillTJ, EastyDL. Spread of virus and distribution of latent infection following ocular herpes simplex in the non-immune and immune mouse. J Gen Virol63:95–101, 1982.
51.
MetcalfJF, WhitleyRJ. Protective immunity against herpetic ocular disease in an outbred mouse model. Curr Eye Res6:167–171, 1987.
52.
SuY-H, OakesJE, LauschRN. Ocular avirulence of a herpes simplex virus type 1 strain is associated with heightened sensitivity to alpha/beta interferon. J Virol64:2187–2192, 1990.
53.
HendricksRL, TumpeyTM, FinneganA.IFN-γ and IL-2 are protective in the skin but pathologic in the corneas of HSV-1-infected mice. J Immunol149:3023–3028, 1992.
54.
TangQ, ChenW, HendricksRL. Proinflammatory functions of IL-2 in herpes simplex virus corneal infection. J Immunol158:1275–1283, 1997.
55.
BishopGA, KumelG, SchwartzSA, GloriosoJC. Specificity of human natural killer cells in limiting dilution culture for determinants of herpes simplex virus type 1 glycoproteins. J Virol57:294–300, 1986.
56.
BishopGA, McCurryL, SchwartzSA, GloriosoJC. Activation of human natural killer cells by herpes simplex virus type 1-infected cells. Intervirology28:7–88, 1987.
57.
BironCA, ByronKS, SullivanJL. Severe herpesvirus infections in an adolescent without natural killer cells. Med Intelligence320:1731–1736, 1989.
58.
MorahanPS, MorseSS, McGeorgeMB. Macrophage extrinsic antiviral activity during herpes simplex virus infection. J Gen Virol46:291–300, 1980.
59.
HayashiK, KurataT, MorishimaT, NasseryT.Analysis of the inhibitory effect of peritoneal macrophages on the spread of herpes simplex virus. Infect Immunol28:350–358, 1980.
NagyRM, McFallRC, SeryTW. Cell-mediated immunity in herpes corneal stromal disease. Invest Ophthalmol Vis Sci19:271–277, 1980.
64.
NewellCK, MartinS, SendeleD, MercadalCM, RouseBT. Herpes simplex virus-induced stromal keratitis: Role of T-lymphocyte subsets in immunopathology. J Virol63:769–775, 1989.
65.
NewellCK, SendeleD, RouseBT. Effects of CD4+ and CD8+ T-lymphocyte depletion on the induction and expression of herpes simplex stromal keratitis. Regional Immunol2:366–369, 1989.
66.
DoymazMZ, FosterCM, DestephanoD, RouseBT. MHC II-restricted, CD4+ cytotoxic T lymphocytes specific for herpes simplex virus-1: Implications for the development of herpetic stromal keratitis in mice. Clin Immunol Immunopathol61:398–409, 1991.
67.
NiemialtowskiMG, RouseBT. Predominance of Th1 cells in ocular tissues during herpetic stromal keratitis. J Immunol149:3035–3039, 1992.
68.
JayaramanS, HeiligenhausA, RodriguezA, SoukiasianS, DorfME, FosterCS. Exacerbation of murine herpes simplex virus-mediated stromal keratitis by Th2 type T cells. J Immunol151:5777–5789, 1993.
69.
MercadalCM, BouleyDM, DeStaphanoD, RouseBT. Herpetic stromal keratitis in the reconstituted scid mouse model. J Virol67:3404–3408, 1993.
KnottsFB, CookML, StevenJG. Pathogenesis of herpetic encephalitis in mice after ophthalmic inoculation. J Infect Dis130:16–27, 1974.
72.
FraserNW, Valyi-NagyT.Viral, neuronal and immune factors which may influence herpes simplex virus (HSV) latency and reactivation. Microb Pathogen15:83–91, 1993.
EnquistLW, HusakPJ, BanfieldBW, SmithGA. Infection and spread of alphaherpesviruses in the nervous system. Adv Virus Res51:239–347, 1998.
75.
StevensJG, CookML. Maintenance of latent herpetic infection: An apparent role for anti-viral IgG. J Immunol113:1685–1693, 1974.
76.
CookML, StevensJG. Restricted replication of herpes simplex virus in spinal ganglia of resistant mice is accompanied by an early infiltration of immunoglobulin G-bearing cells. Infect Immunol40:752–758, 1983.
77.
MitchellBM, StevensJG. Neuroinvasive properties of herpes simplex virus type 1 glycoprotein variants are controlled by the immune response. J Immunol156:246–255, 1996.
78.
Valyi-NagyT, DeshmaneSL, RaengsakulrachB, NicosiaM, GesserRM, WysockaM, DillnerA, FraserNW. Herpes simplex virus type 1 mutant strain in 1814 establishes a unique, slowly progressing infection in SCID mice. J Virol66:7336–7345, 1992.
79.
GesserRM, Valyi-NagyT, FraserNW. Restricted herpes simplex virus type 1 gene expression within sensory neurons in the absence of functional B and T lymphocytes. Virology200:791–795, 1994.
80.
EllisonAR, YangL, VoytekC, MargolisTP. Establishment of latent herpes simplex virus type 1 infection in resistant, sensitive, and immunodeficient mouse strains. Virology268:17–28, 2000.
81.
SekizawaT, OpenshawH, WohlenbergC, NotkinsAL. Latency of herpes simplex virus in absence of neutralizing antibody: Model for reactivation. Science210:1026–1028, 1980.
82.
Valyi-NagyT, FareedMU, O'KeefeJS, GesserRM, MacLeanAR, BrownSM, SpivackJG, FraserNW. The herpes simplex virus type 1 strain 17+γ34.5 deletion mutant 1716 is avirulent in SCID mice. J Gen Virol75:2059–2063, 1994.
83.
SimmonsA, TscharkeDC. Anti-CD8 impairs clearance of herpes simplex virus from the nervous system: Implications for the fate of virally infected neurons. J Exp Med175:1337–1344, 1992.
84.
LiuT, KhannaKM, ChenXP, FinkDJ, HendricksRL. CD8+ T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons. J Exp Med191:1459–1466, 2000.
85.
SmithPM, WolcottRM, ChervenakR, JenningsSR, Control of acute herpes simplex virus infection: T cell-mediated viral clearance is dependent upon interferon-γ (IFN-γ). Virology202:76–88, 1994.
86.
CantinEM, HintonDR, ChenJ, OpenshawH.Gamma interferon expression during acute and latent nervous system infection by herpes simplex virus type 1. J Virol69:4898–4905, 1995.
87.
HalfordWP, GebhardtBM, CarrDJJ. Persistent cytokine expression in trigeminal ganglion latently infected with herpes simplex virus type 1. J Immunol157:3542–3549, 1996.
88.
CantinE, TanamachiB, OpenshawH.Role for gamma interferon in control of herpes simplex virus type 1 reactivation. J Virol73:3418–3423, 1999.
89.
HillAB, BarnettBC, McMichaelAJ, McGeochDJ. HLA class I molecules are not transported to the cell surface in cells infected with herpes simplex virus types 1 and 2. J Immunol152:2736–2741, 1994.
90.
YorkIA, RoopC, AndrewsDW, RiddellSR, GrahamFL, JohnsonDC. A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes. Cell77:525–535, 1994.
91.
HillA, JugovicP, YorkI, RussG, BenninkJ, YewdellJ, PloeghH, JohnsonD.Herpes simplex virus turns off the TAP to evade host immunity. Nature375:411–415, 1995.
92.
SongG-Y, DeJongG, JiaW.Cell surface expression of MHC molecules in glioma cells infected with herpes simplex virus type-1. J Neuroimmunol93:1–7, 1999.
93.
JeromeKR, TaitJF, KoelleDM, CoreyL.Herpes simplex virus type 1 renders infected cells resistant to cytotoxic T-lymphocyte-induced apoptosis. J Virol72:436–441, 1998.
94.
JeromeKR, FoxR, ChenZ, SearsAE, LeeH-Y, CoreyL.Herpes simplex virus inhibits apoptosis through the action of two genes, Us5 and Us3. J Virol73:8950–8957, 1999.
95.
ItoM, WatanabeM, KamiyaH, SakuraiM.Herpes simplex virus type 1 induces apoptosis in peripheral blood T lymphocytes. J Infect Dis175:1220–1224, 1997.
96.
RafteryMJ, BehrensCK, MüllerA, KrammerPH, WalczakH, SchnrichG.Herpes simplex virus type 1 infection of activated cytotoxic T cells: Induction of fratricide as a mechanism of viral immune evasion. J Exp Med190:1103–1113, 1999.
97.
Mendez-SamperioP, HernandezM, AyalaHE. Induction of transforming growth factor-β1 by herpes simplex virus. J. Interferon Cytokine Res20:273–280, 2000.
98.
LeeYJ, HanY, LuHT, NguyenV, QinH, HowePH, HocevarBA, BossJM, RansohoffRM, BenvenisteEN. TGF-β suppresses IFN-γ induction of class II MHC gene expression by inhibiting class II transactivator messenger RNA expression. J Immunol158:2065–2075, 1997.
99.
BelandJL, SobelRA, AdlerH, Del-PanNC, RimmIJ. B cell-deficient mice have increased susceptibility to HSV-1 encephalomyelitis and mortality. J Neuroimmunol94:122–126, 1999.
100.
MikloskaZ, SannaPP, CunninghamAL. Neutralizing antibodies inhibit axonal spread of herpes simplex virus type 1 to epidermal cells in vitro. J Virol73:5934–5944, 1999.
101.
Da CostaXJ, BrockmanMA, AlicotE, MaM, FischerMB, ZhouX, KnipeDM, CarrollMC. Humoral response to herpes simplex virus is complement-dependent. Proc Natl Acad Sci U S A96:12708–12712, 1999.
102.
BaronS, TyringSK, FleischmannWRJr, CoppenhaverDH, NieselDW, KlimpelGR, StantonGJ, HughesTK. The InterferonsL: Mechanisms of action and clinical applications. J Am Med Assoc266:1375–1383, 1991.
103.
LeibDA, HarrisonTE, LasloKM, MachalekMA, MoormanNJ, VirginHW. Interferons regulate the phenotype of wild-type and mutant herpes simplex viruses in vivo. J Exp Med189:663–672, 1999.
104.
MossmanKL, SaffranHA, SmileyJR. Herpes simplex virus ICPO mutants are sensitive to interferon. J Virol74:2052–2056, 2000.
105.
ThomasSK, GoughG, LatchmanDS, CoffinRS. Herpes simplex virus latency-associated transcript encodes a protein which greatly enhances virus growth, can compensate for deficiencies in immediate-early gene expression, and is likely to function during reactivation from virus latency. J Virol73:6618–6625, 1999.
PerngG-C, DunkelEC, GearyPA, SlaninaSM, GhiasiH, KaiwarR, NesburnAB, WechslerSL. The latency-associated transcript gene of herpes simplex virus type 1 (HSV-1) is required for efficient in vivo spontaneous reactivation of HSV-1 from latency. J Virol68:8045–8055, 1994.
108.
SawtellNM. The probability of in vivo reactivation of herpes simplex virus type 1 increases with the number of latently infected neurons in the ganglia. J Virol72:6888–6892, 1998.
109.
ShimeldC, WhitelandJL, NichollsSM, GrinfeldE, EastyDL, GaoH, HillTJ. Immune cell infiltration and persistence in the mouse trigeminal ganglion after infection of the cornea with herpes simplex virus type 1. J Neuroimmunol61:7–16, 1995.
110.
LiuT, TangQ, HendricksRL. Inflammatory infiltration of the trigeminal ganglion after herpes simplex virus type 1 corneal infection. J Virol70:264–271, 1996.
111.
CarrDJJ, HalfordWP, VeressLA, NoisakranS, PerngG-C, WechslerSL. The persistent elevated cytokine mRNA levels in trigeminal ganglia of mice latently infected with HSV-1 are not due to the presence of latency associated transcript (LAT) RNAs. Virus Res54:1–8, 1998.
112.
HalfordWP, GebhardtBM, CarrDJJ. Acyclovir blocks cytokine gene expression in trigeminal ganglia latently infected with herpes simplex virus type 1. Virology238:53–63, 1997.
113.
CarrDJJ, CampbellIL. Transgenic expression of interleukin-6 in the central nervous system confers protection against acute herpes simplex virus type-1 infection. J Neuro Virol5:449–457, 1999.
114.
LeBlancRA, PesnicakL, CabralES, GodleskiM, StrausSE. Lack of interleukin-6 (IL-6) enhances susceptibility to infection but does not alter latency or reactivation of herpes simplex virus type 1 in IL-6 knockout mice. J Virol73:8145–8151, 1999.
115.
ShimeldC, EastyDL, HillTJ. Reactivation of herpes simplex virus type 1 in the mouse trigeminal ganglion: An in vivo study of virus antigen and cytokines. J Virol73:1767–1773, 1999.
116.
PereiraRA, TscharkeDC, SimmonsA.Upregulation of class I major histocompatibility complex gene expression in primary sensory neurons, satellite cells, and Schwann cells of mice in response to acute but not latent herpes simplex virus infection in vivo. J Exp Med180:841–850, 1994.
117.
PereiraRA, SimmonsA.Cell surface expression of H2 antigens on primary sensory neurons inn response to acute but not latent herpes simplex virus infection in vivo. J Virol73:6484–6489, 1999.
118.
IkemotoK, PollardRB, FukumotoT, MorimatsuM, SuzukiF.Small amounts of exogenous IL-4 increase the severity of encephalitis induced in mice by the intranasal infection of herpes simplex virus type 1. J Immunol155:1326–1333.
119.
GhiasiH, CaiS, SlaninaSM, PerngG-C, NesburnAB, WechslerSL. The role of interleukin (IL)-2 and IL-4 in herpes simplex virus type 1 ocular replication and eye disease. J Infect Dis179:1086–1093, 1999.
120.
CarrDJJ, NoisakranS, HalfordWP, LukacsN, AsenioV, CampbellIL. Cytokine and chemokine production in HSV-1 latently infected trigeminal ganglion cell cultures: Effects of hyperthermic stress. J Neuroimmunol85:111–121, 1998.
121.
NoisakranS, CarrDJJ. Lymphocytes delay kinetics of HSV-1 reactivation from in vitro explants of latent infected trigeminal ganglia. J Neuroimmunol95:126–135, 1999.
122.
KrieselJD, AraneoBA, PetajanJP, SpruanceSL, StromattS.Herpes labialis associated with recombinant human ciliary neurotrophic factor. J Infect Dis170:1046, 1994.
NoisakranS, HalfordWP, VeressL, CarrDJJ. Role of the hypothalamic pituitary adrenal axis and IL-6 in stress-induced reactivation of latent herpes simplex virus type 1. J Immunol160:5441–5447, 1998.
126.
BakerM, NoisakranS, GebhardtBM, KrieselJD, CarrDJJ. The relationship between interleukin-6 and herpes simplex virus type 1: Implications for behavior and immunopathology. Brain Behavior Immunol13:201–211, 1999.
127.
BertiR, JacobsonS.Role of viral infection in the aetiology of multiple sclerosis: Status of current knowledge and therapeutic implications. CNS Drugs12:1–7, 1999.
128.
GebhardtBM. Evidence for antigenic cross-reactivity between herpes virus and the acetylcholine receptor. J Neuroimmunol105:145–153, 2000.
129.
BoulikasT.Status of gene therapy in 1997: Molecular mechanisms, disease targets, and clinical applications. Gen Ther Mol Biol1:1–172, 1998.
130.
NanniP, ForniG, LolliniPL. Cytokine gene therapy: Hopes and pitfalls. Ann Oncol10:261–266, 1999.
131.
MarshallE.Less hype, more biology needed for gene therapy. Science270:1751, 1995.
132.
ColosimoA, GonczKK, HolmesAR, KunzelmannK, NovelliG, MaloneRW, BennettMJ, GruenertDC. Transfer and expression of foreign genes in mammalian cells. BioTechniques29:314–318, 2000.
133.
Xiao-LingL, MadanmohanB, XiaoW, DhananjayaVK, HasselBA. Induction of interferon synthesis and activation of interferon stimulated genes by liposomal transfection reagents. J Interferon Cytokine Res18:947–952, 1998.
134.
ChunS, DaheshiaM, LeeS, EoSK, RouseBT. Distribution fate and mechanism of immune modulation following mucosal delivery of plasmid DNA encoding IL-10. J Immunol163:2393–2402, 1999.
135.
TakagiT, HashiguchiM, MahatoR, TokudaH, TakakuraY, HashidaM.Involvement of specific mechanism in plasmid DNA uptake by mouse peritoneal macrophages. Biochem Biophys Res Commun245:729–733, 1998.
136.
NakamuraM, Davila-ZavalaP, TokudaH, TakakuraY, HashidaM.Uptake and gene expression of naked plasmid DNA in cultured brain microvessel endothelial cells. Biochem Biophys Res Commun245:235–239, 1998.
137.
TakakuraY, TakagiT, HashiguchiM, NishikawaM, YamashitaF, DoiT, ImanishiT, SuzukiH, KodamaT, HashidaM.Characterization of plasmid DNA binding and uptake by peritoneal macrophages from class A scavenger receptor knockout mice. Pharm Res16:503–508, 1999.
138.
WellsDJ. Gene Therapy via Transmuscular Infection of Plasmid DNA. London: Chapman and Hall, pp83–103, 1995.
139.
LawsonCM, YeowWS, LeeCM, BeilharzMW. In vivo expression of an interferon-alpha gene by intramuscular injection of naked DNA. J Interferon Cytokine Res17:255–261, 1997.
140.
YeowWS, LawsonCM, BeilharzMW. Antiviral activities of individual murine IFN-alpha subtypes in vivo: Intramuscular injection of IFN expression constructs reduces cytomegalovirus replication. J Immunol160:2932–2939, 1998.
141.
The Herpetic Eyes Studies Group. Acyclovir for the prevention of recurrent herpes simplex virus eye disease. N Engl J Med 339:300–306, 1998.
142.
ChakrabartiS, PillayD, RatcliffeD, CanePA, CollinghamKE, MilliganDW. Resistance to antiviral drugs in herpes simplex virus infections among allogenetic stem cell transplant recipients: Risk factors and prognostic significance. J Infect Dis181:2055–2058, 2000.
143.
PramodNP, ThyagarajanSP, MohanKV, AnandakannanK.Acyclovir resistance in herpes simplex virus isolates from keratitis cases: An analysis from a developing country. Microbiol Immunol44:241–247, 2000.
144.
DaheshiaM, KuklinN, KanangatS, ManickanE, RouseBT. Suppression of ongoing ocular inflammatory disease by topical administration of plasmid DNA encoding IL-10. J Immunol159:1945–1952, 1997.
145.
BabuJS, KanangatS, RouseBT. T cell cytokine mRNA expression during the course of the immunopathologic ocular disease herpetic stromal keratitis. J Immunol154:4822–4829, 1995.
146.
CarrDJJ, VeressLA, NoisakranS, CampbellIL. Astrocyte-targeted expression of IFN-alpha1 protects mice from acute ocular herpes simplex virus type 1 infection. J Immunol161:4859–4865, 1998.
147.
NoisakranS, CampbellIL, CarrDJJ. Ectopic expression of DNA encoding IFN-alpha 1 in the cornea protects mice from herpes simplex virus type 1-induced encephalitis. J Immunol162:4184–4190, 1999.
148.
NoisakranS, CarrDJJ. Plasmid DNA encoding IFN-alpha 1 antagonizes herpes simplex virus type 1 ocular infection through CD4+ and CD8+ T lymphocytes. J Immunol164:6435–6443, 2000.
149.
CuiB, CarrDJJ. A plasmid construct encoding murine interferon beta antagonizes the replication of herpes simplex virus type I in vitro and in vivo. J Neuroimmunol108:92–102, 2000.
